Sbaraglia G, Cenci E, Vecchiarelli A, Perito S
Boll Soc Ital Biol Sper. 1980 Oct 15;56(19):1969-75.
The effect of administration of BCG in association with chemotherapy in histocompatible CD2F1 mice challenged ip with Moloney-virus-induced lymphoma LSTRA of Balb/c origin was studied. All untreated mice died with comparable median survival time (MST). Immunochemotherapy experiments were performed in histocompatible mice using BCG according to various treatment schedules with respect to tumor challenge and 3 nitrosureas of clinical interest (i.e. BCNU, MeCCNU and CCNU) administration. If recipients were subjected to ip treatment with drugs alone or in association with the non specific immunoadjuvant (IA) given after tumor challenge (on day +1); no significant antitumor effect was detected. Synergistic antitumor effects were evidenced when the antineoplastic agents were associated with IA administered on the "-14+1" regimen with respect to the tumor. The results pointed out that the antilymphoma effects of chemotherapy could be amplified by IA only when the treatment schedule included adjuvants administration prior to tumor challenge.
研究了在组织相容性的CD2F1小鼠中，腹腔注射源自Balb/c的莫洛尼病毒诱导的淋巴瘤LSTRA后，卡介苗（BCG）与化疗联合应用的效果。所有未治疗的小鼠均在相当的中位生存时间（MST）内死亡。在组织相容性小鼠中，根据肿瘤攻击和3种具有临床意义的亚硝基脲（即卡莫司汀、司莫司汀和洛莫司汀）给药的不同治疗方案，使用卡介苗进行免疫化疗实验。如果接受者在肿瘤攻击后（第+1天）单独接受腹腔内药物治疗或与非特异性免疫佐剂（IA）联合治疗，则未检测到明显的抗肿瘤作用。当抗肿瘤药物与在肿瘤攻击前“-14 + 1”方案给药的IA联合使用时，可证明有协同抗肿瘤作用。结果指出，只有当治疗方案包括在肿瘤攻击前给予佐剂时，IA才能增强化疗的抗淋巴瘤作用。
